9xchange is a biopharma marketplace
creating transparency, enabling you to monetize your pipeline and discover assets you did not know were available
kiss fewer frogs
a better way to find and do the right biopharma deals. networking is for relationships, not discovery
9xchange accelerates dealmaking, creates options, and is relevant - everything listed is available to transact
Thaminda Ramanayake, VP, Global Head of BD, Oncology, Sanofi
biotech
monetize assets to buy runway or fill your pipeline. survive or grow, leveraging market conditions
pharma
find assets you did not know were available, including ones released by your peers
investor, entrepreneur
discover available, industry-grade substrate to build or augment companies; help portfolios
ANNOUNCING

BenevolentAI partnership
advanced AI technology identifies new indications for your assets, and as a result, suggests buyers you would not have considered engaging with

LEARN MORE
built by industry leaders across pharma, biotech, VC
the people behind 9xchange. Click the small 9xchange logo to connect with us on 9xchange.
Anat Naschitz is CEO and Co-founder of 9xchange, the marketplace for biopharma assets
anat naschitz
CEO & CO-FOUNDER
investor, company and fund creator
co-founder and partner, OrbiMed Israel. previously senior roles at McKinsey and Apax
Jan Schultink is Co-founder of 9xchange, the marketplace for biopharma assets
jan schultink
CO-FOUNDER
tech entrepreneur. founded and built SlideMagic, international authority in presentation design. senior roles at McKinsey
Jeremy Levin is a member of the Advisory Board of 9xchange, the marketplace for biopharma assets
jeremy levin
ADVISORY BOARD
chairman and CEO, OvidRx. chairman, Opthea. Board member, Lundbeck. vice chair, BIO
CEO, Teva. SVP BD, BMS. global head of BD, Novartis. chair, BIO
Melanie Lee is a member of the Advisory Board of 9xchange, the marketplace for biopharma assets
melanie lee
ADVISORY BOARD
CEO, LifeArc. board member, Sanofi. board trustee, UK Dementia Research. CSO, BTG. CEO, Nighstar (Biogen). CEO, Syntaxin (Ipsen). board, Lundbeck. EVP, UCB
John McHutchison is a member of the Advisory Board of 9xchange, the marketplace for biopharma assets
john mchutchison
ADVISORY BOARD
CEO, Assembly. CSO, head of R&D, Gilead - developed curative drugs for hepatitis C and HBV through approval. AD Duke Clinical Research. Scripps Research Foundation. USC
Paul Biondi is a member of the Advisory Board of 9xchange, the marketplace for biopharma assets
paul biondi
ADVISORY BOARD
executive partner, president, Flagship Pioneering Medicines. boards incl. Seres, Valo
SVP Strategy, BD, BMS. R&D leadership roles, BMS. principal, Mercer
Paul Sekhri is a member of the Advisory Board of 9xchange, the marketplace for biopharma assets
paul sekhri
ADVISORY BOARD
CEO, vTv. 30 boards eg Ipsen, Veeva. CEO Lycera, eGenesis, Cerimon. SVP IC Sanofi. Chief Strategy/BD, Teva. op.partner, TPG Biotech. CBO Ariad. SVP BD&L Novartis
you control what to reveal
you can be specific about your asset or wish without disclosing your strategy - anonymous by default. reveal more to a specific person with increasing trust
AS FEATURED IN


repurpose, derisk, discover
ai/ml network across technologies to uncover new value or lay out a safe way to proceed. more options to the owner, larger potential buyer universe
invitation-only
curated member base of people you would want to work with - your network and ours, covering the entire industry. biotech, pharma, investors, entrepreneurs
APPLY
save time and reduce noise
a beautiful, convenient application with all your assets, wishes, deals, data, agreements and connections in one place. communicate with your team and other 9xchange members, always in the right context
- support contact privacy news